US 12,479,916 B2
Antigen-binding molecule containing modified antibody variable region
Tomoyuki Igawa, Shizuoka (JP); Shojiro Kadono, Kanagawa (JP); Naoka Hironiwa, Shizuoka (JP); and Mika Sakurai, Shizuoka (JP)
Assigned to Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed by Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed on Jun. 30, 2023, as Appl. No. 18/345,750.
Application 18/345,750 is a division of application No. 16/704,464, filed on Dec. 5, 2019, granted, now 11,739,149.
Application 16/704,464 is a division of application No. 15/035,098, abandoned, previously published as PCT/JP2014/079785, filed on Nov. 11, 2014.
Claims priority of application No. JP2013-232803 (JP), filed on Nov. 11, 2013.
Prior Publication US 2024/0026000 A1, Jan. 25, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); C07K 16/30 (2006.01); C07K 16/42 (2006.01)
CPC C07K 16/2809 (2013.01) [C07K 16/2848 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2875 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/4283 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/70 (2013.01)] 19 Claims
 
1. An antigen-binding molecule comprising a first antibody variable region comprising a first antigen-binding site and a second antigen-binding site, wherein:
(a) the first antigen-binding site recognizes a first antigen that is human CD3;
(b) the second antigen-binding site recognizes a second antigen that is a human Toll-like receptor 2;
(c) the first antigen-binding site cannot bind to the first antigen when the second antigen-binding site is bound to the second antigen;
(d) the second antigen-binding site cannot bind to the second antigen when the first antigen-binding site is bound to the first antigen; and
(e) the first antibody variable region comprises:
a heavy chain variable domain comprising the heavy chain variable domain amino acid sequence in any one of SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 40, and
a light chain variable domain comprising the light chain variable domain amino acid sequence in SEQ ID NO: 23.